<p>Inhibikase Therapeutics, Inc.（紐約證券交易所代碼：IKT - 免費報告）- Lifesci Capital 在 12 月 1 日（星期一）發佈的報告中發佈了 Inhibikase Therapeutics 的 2025 財年每股收益（EPS）預估。Lifesci Capital 分析師 C. Jubinville 預計該公司將在本年度發佈每股收益（$0.57）。Inhibikase Therapeutics 當前全年的共識預估為每股收益（$0.97）。Lifesci Capital 還發布了 Inhibikase Therapeutics 2025 年第四季度每股收益預估為（$0.12），2026 財年每股收益預估為（$1.00），2027 財年每股收益預估為（$1.00），2028 財年每股收益預估為（$1.10）以及 2029 財年每股收益預估為（$1.00）。</p>
<h2>Inhibikase Therapeutics 股價下跌 6.0%</h2>
<p>Inhibikase Therapeutics 的股票在星期三開盤價為$1.41。該公司的市值為 1.06 億美元，市盈率為-0.53，貝塔值為 0.89。Inhibikase Therapeutics 的 1 年最低價為$1.33，1 年最高價為$4.20。該公司的 50 日移動平均價為$1.57，200 日移動平均價為$1.71。</p>
<h2>Inhibikase Therapeutics 的機構交易</h2>
<p>幾家大型投資者最近增加或減少了對 IKT 的持股。Geode Capital Management LLC 在第二季度將其在 Inhibikase Therapeutics 的持股增加了 228.5%。Geode Capital Management LLC 目前擁有 1,066,700 股該公司的股票，價值$2,080,000，在此期間又購買了 741,940 股。ADAR1 Capital Management LLC 在第三季度將其在 Inhibikase Therapeutics 的持股增加了 2.5%。ADAR1 Capital Management LLC 目前擁有 5,247,603 股該公司的股票，價值$8,501,000，在上個季度又購買了 125,498 股。高盛集團在第一季度將其在 Inhibikase Therapeutics 的持股增加了 277.7%。高盛集團目前擁有 166,025 股該公司的股票，價值$364,000，在此期間又購買了 122,073 股。Jane Street Group LLC 在第一季度購買了 Inhibikase Therapeutics 的新股份，價值約為$255,000。最後，Citadel Advisors LLC 在第三季度購買了 Inhibikase Therapeutics 的新股份，價值約為$116,000。機構投資者持有該公司 3.81% 的股票。</p>
<h2>關於 Inhibikase Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Inhibikase Therapeutics, Inc.是一家臨牀階段的製藥公司，開發用於帕金森病及相關疾病的治療藥物。其主要產品候選藥物是 IkT-148009，一種非受體 Abelson 酪氨酸激酶抑制劑，目前正在進行帕金森病和胃腸道治療的 2a 期臨牀試驗。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票超過 Inhibikase Therapeutics</li>
<li>如何投資生物科技股票</li>
<li>Palantir 股票找到立足點——並走向全球增長</li>
<li>股票拆分意味着什麼？</li>
<li>1 億美元的信號：跟隨聰明資金進入 DoorDash</li>
<li>銀行股票 - 最值得投資的銀行股票</li>
<li>華爾街的沉睡巨人：亞馬遜即將覺醒嗎？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Inhibikase Therapeutics 嗎？</h2>
<p>在你考慮 Inhibikase Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Inhibikase Therapeutics 並不在名單上。</p>
<p>雖然 Inhibikase Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

<p>Lifesci Capital 發佈了 Inhibikase Therapeutics 2025 財年的每股收益（EPS）預測，預計每股收益為（$0.57）。當前全年的共識預期為每股（$0.97）虧損。Lifesci 還提供了未來幾年的預測，2026 財年預計每股（$1.00）虧損，2029 財年預計每股（$1.00）虧損。Inhibikase 股票下跌 6.0%，市值為 1.06 億美元。機構投資者已調整在該公司的持股。Inhibikase 開發用於帕金森病的治療藥物，其主要產品正在進行 2a 期臨牀試驗</p>

<p>Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - Lifesci Capital issued their FY2025 EPS estimates for Inhibikase Therapeutics in a report issued on Monday, December 1st. Lifesci Capital analyst C. Jubinville expects that the company will post earnings of ($0.57) per share for the year. The consensus estimate for Inhibikase Therapeutics' current full-year earnings is ($0.97) per share. Lifesci Capital also issued estimates for Inhibikase Therapeutics' Q4 2025 earnings at ($0.12) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at ($1.00) EPS.</p>
<div class="lb-trans"><p>Inhibikase Therapeutics, Inc.（紐約證券交易所代碼：IKT - 免費報告）- Lifesci Capital 在 12 月 1 日（星期一）發佈的報告中發佈了 Inhibikase Therapeutics 的 2025 財年每股收益（EPS）預估。Lifesci Capital 分析師 C. Jubinville 預計該公司將在本年度發佈每股收益（$0.57）。Inhibikase Therapeutics 當前全年的共識預估為每股收益（$0.97）。Lifesci Capital 還發布了 Inhibikase Therapeutics 2025 年第四季度每股收益預估為（$0.12），2026 財年每股收益預估為（$1.00），2027 財年每股收益預估為（$1.00），2028 財年每股收益預估為（$1.10）以及 2029 財年每股收益預估為（$1.00）。</p>
</div><h2>Inhibikase Therapeutics Trading Down 6.0%</h2>
<div class="lb-trans"><h2>Inhibikase Therapeutics 股價下跌 6.0%</h2>
</div><p>Inhibikase Therapeutics stock opened at $1.41 on Wednesday. The firm has a market cap of $106.00 million, a P/E ratio of -0.53 and a beta of 0.89. Inhibikase Therapeutics has a 1-year low of $1.33 and a 1-year high of $4.20. The firm has a 50-day moving average of $1.57 and a 200-day moving average of $1.71.</p>
<div class="lb-trans"><p>Inhibikase Therapeutics 的股票在星期三開盤價為$1.41。該公司的市值為 1.06 億美元，市盈率為-0.53，貝塔值為 0.89。Inhibikase Therapeutics 的 1 年最低價為$1.33，1 年最高價為$4.20。該公司的 50 日移動平均價為$1.57，200 日移動平均價為$1.71。</p>
</div><h2>Institutional Trading of Inhibikase Therapeutics</h2>
<div class="lb-trans"><h2>Inhibikase Therapeutics 的機構交易</h2>
</div><p>Several large investors have recently added to or reduced their stakes in IKT. Geode Capital Management LLC lifted its position in shares of Inhibikase Therapeutics by 228.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,066,700 shares of the company's stock worth $2,080,000 after purchasing an additional 741,940 shares during the period. ADAR1 Capital Management LLC raised its stake in Inhibikase Therapeutics by 2.5% in the third quarter. ADAR1 Capital Management LLC now owns 5,247,603 shares of the company's stock worth $8,501,000 after buying an additional 125,498 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Inhibikase Therapeutics by 277.7% in the first quarter. Goldman Sachs Group Inc. now owns 166,025 shares of the company's stock worth $364,000 after buying an additional 122,073 shares during the period. Jane Street Group LLC bought a new stake in Inhibikase Therapeutics during the 1st quarter valued at approximately $255,000. Finally, Citadel Advisors LLC bought a new stake in Inhibikase Therapeutics during the 3rd quarter valued at approximately $116,000. Institutional investors own 3.81% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近增加或減少了對 IKT 的持股。Geode Capital Management LLC 在第二季度將其在 Inhibikase Therapeutics 的持股增加了 228.5%。Geode Capital Management LLC 目前擁有 1,066,700 股該公司的股票，價值$2,080,000，在此期間又購買了 741,940 股。ADAR1 Capital Management LLC 在第三季度將其在 Inhibikase Therapeutics 的持股增加了 2.5%。ADAR1 Capital Management LLC 目前擁有 5,247,603 股該公司的股票，價值$8,501,000，在上個季度又購買了 125,498 股。高盛集團在第一季度將其在 Inhibikase Therapeutics 的持股增加了 277.7%。高盛集團目前擁有 166,025 股該公司的股票，價值$364,000，在此期間又購買了 122,073 股。Jane Street Group LLC 在第一季度購買了 Inhibikase Therapeutics 的新股份，價值約為$255,000。最後，Citadel Advisors LLC 在第三季度購買了 Inhibikase Therapeutics 的新股份，價值約為$116,000。機構投資者持有該公司 3.81% 的股票。</p>
</div><h2>About Inhibikase Therapeutics</h2>
<div class="lb-trans"><h2>關於 Inhibikase Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.</p>
<div class="lb-trans"><p>Inhibikase Therapeutics, Inc.是一家臨牀階段的製藥公司，開發用於帕金森病及相關疾病的治療藥物。其主要產品候選藥物是 IkT-148009，一種非受體 Abelson 酪氨酸激酶抑制劑，目前正在進行帕金森病和胃腸道治療的 2a 期臨牀試驗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Inhibikase Therapeutics</li>
<li>How to Invest in Biotech Stocks</li>
<li>Palantir Stock Finds Its Footing—and a Path to Global Growth</li>
<li>What Does a Stock Split Mean?</li>
<li>The $100 Million Tell: Following Smart Money Into DoorDash</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Inhibikase Therapeutics</li>
<li>如何投資生物科技股票</li>
<li>Palantir 股票找到立足點——並走向全球增長</li>
<li>股票拆分意味着什麼？</li>
<li>1 億美元的信號：跟隨聰明資金進入 DoorDash</li>
<li>銀行股票 - 最值得投資的銀行股票</li>
<li>華爾街的沉睡巨人：亞馬遜即將覺醒嗎？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inhibikase Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Inhibikase Therapeutics 嗎？</h2>
</div><p>Before you consider Inhibikase Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Inhibikase Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Inhibikase Therapeutics 並不在名單上。</p>
</div><p>While Inhibikase Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Inhibikase Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Lifesci Capital 發佈了對 Inhibikase Therapeutics（IKT）2025 財年收益的預估